Description:

Systemic Mastocytosis - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Systemic Mastocytosis - Pipeline Review, H1 2016’, provides an overview of the Systemic Mastocytosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Systemic Mastocytosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Mastocytosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Systemic Mastocytosis
- The report reviews pipeline therapeutics for Systemic Mastocytosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental
activities
- The report reviews key players involved Systemic Mastocytosis therapeutics and enlists all their major and minor projects
- The report assesses Systemic Mastocytosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Systemic Mastocytosis

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Systemic Mastocytosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Systemic Mastocytosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents:
Late Stage Products
Clinical Stage Products
Early Stage Products
Systemic Mastocytosis - Products under Development by Companies
Systemic Mastocytosis - Companies Involved in Therapeutics Development
AB Science SA
AbbVie Inc.
Allakos Inc.
Arog Pharmaceuticals, Inc.
Blueprint Medicines Corporation
Bristol-Myers Squibb Company
Deciphera Pharmaceuticals, LLC
Novartis AG
Patara Pharma, Inc.
Stemline Therapeutics, Inc.
Systemic Mastocytosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AK-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BLU-285 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
crenolanib besylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cromolyn sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dasatinib - Drug Profile
Product Description
May 02, 2016: AB Science has submitted to EMA the marketing authorization application for Masitinib in the Treatment of Severe Systemic Mastocytosis
Feb 01, 2016: AB Science announces that Rapporteurs appointed by the EMA have recommended to file a marketing authorization application for full approval for masitinib in severe systemic mastocytosis
Dec 07, 2015: AB Science announces results from Phase 3 randomized placebo-controlled trial of masitinib in adults with severe systemic mastocytosis unresponsive to optimal symptomatic treatment
Nov 30, 2015: AB Science Announces Positive Top-Line Results from Phase 3 Trial of Masitinib in Adults with Severe Systemic Mastocytosis
Sep 10, 2015: Blueprint Medicines Receives FDA Authorization to Advance Novel Drug Candidate into Clinical Trial for Systemic Mastocytosis
Dec 08, 2014: Blueprint Medicines Debuts Comprehensive Preclinical Data Set on First Selective Drug for Patients with Systemic Mastocytosis at 2014 American Society of Hematology Annual
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 12
Assessment by Monotherapy Products, H1 2016 25
Number of Products by Top 10 Targets, H1 2016 26
Number of Products by Stage and Top 10 Targets, H1 2016 26
Number of Products by Top 10 Mechanism of Actions, H1 2016 28
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 28
Number of Products by Routes of Administration, H1 2016 30
Number of Products by Stage and Routes of Administration, H1 2016 30
Number of Products by Molecule Types, H1 2016 32
Number of Products by Stage and Molecule Types, H1 2016 32

Companies Mentioned:

AB Science SA
AbbVie Inc.
Allakos Inc.
Arog Pharmaceuticals, Inc.
Blueprint Medicines Corporation
Bristol-Myers Squibb Company
Deciphera Pharmaceuticals, LLC
Novartis AG
Patara Pharma, Inc.
Stemline Therapeutics, Inc.

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Global License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.
Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Global License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Source URL: https://www.marketresearchreports.com/global-markets-direct/systemic-mastocytosis-pipeline-review-h1-2016

Links